AtCor Medical (ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new agreement with a major international pharmaceutical company to supply SphygmoCor systems and clinical trials support services. The US$955,000 contract is a new agreement with an existing AtCor customer. A large portion of the contract value will be recognised in the current financial year. AtCor has an ongoing pipeline of new business opportunities and anticipates additional pharmaceutical contracts in the current financial year.
“This is a significant contract, which confirms AtCor’s strong market position as the leading provider of noninvasive central blood pressure measurement in clinical trials. The new agreement demonstrates that AtCor’s growing reputation for high levels of customer satisfaction is being recognised through expanded business with long-term clients,” said Duncan Ross, CEO of AtCor Medical. “Scientific publications continue to reinforce the importance of using central blood pressure as a measurement,” Ross continued. “Using our SphygmoCor technology, the US National Institutes of Health (NIH) Strong Heart Study showed that increased central pressure is associated with cardiovascular risk. It found that when central pulse pressure rises above 50 mm Hg, patient risk of heart attack, stroke, and kidney disease nearly doubles while no such association was shown for brachial pulse pressure measurements taken at the arm. Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and in assuring drug safety. It is equally important in patient care.”
AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe.